|
|
| Enbrel |
All Financial Data in US $ (mln) |
|
Word Search (Top 10 - by date)
|
The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
Genomic Health
(May 16, 2013)
|
Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Novartis
(May 10, 2013)
|
CEL-SCI Presents Data Showing LEAPS Vaccine is Successful in Reducing Rheumatoid Arthritis Index Score in a Second Animal Model
CEL-SCI
(May 06, 2013)
|
Prometheus Launches New Adalimumab Drug And Antibody Levels Monitoring Test
Nestlé
(April 30, 2013)
|
Pfizer Reports First-Quarter 2013 Results
Pfizer
(April 30, 2013)
|
Safeguard Scientifics Announces First Quarter 2013 Financial Results
Sotera Wireless
(April 25, 2013)
|
Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
Amgen
(April 23, 2013)
|
XELJANZ® (tofacitinib citrate) Approved in Japan for the Treatment of Adults with Rheumatoid Arthritis (RA)
Pfizer
(March 25, 2013)
|
Protalix BioTherapeutics Receives Approval to Initiate Phase I Study in Gaucher Patients with PRX-112, an Orally-administered Candidate for the Treatment of Gaucher Disease
Protalix BioTherapeutics
(March 07, 2013)
|
Blaze Bioscience Announces Completion of Series A Financing - Brings Total Investment to $9.8 Million
Blaze Bioscience
(February 22, 2013)
|
|
|
|
|
EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.
|
|
Product Sales Summary 2009/10
|
|
Annual Sales WW - Sales
|
Growth per Year (%)
|
|
Rank1 |
Generic Name
|
Therapeutic Subcategory
|
2010 |
| Enbrel2 |
|
|
|
7,257 |
|
|
|
|
Clinical Trial Coverage: No. of Trials involving Product
|
|
|
|
Welcome
Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.
Explore Evaluate
Partnering
EvaluatePharma® now includes Partnering Opportunities - products available for licensing.
Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.
Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.
Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.
Register to access more FREE content:
- 2011 Product Sales analysis
- Download analysis into Excel
- Search 2 yrs of company press releases
Register for Free Analysis
Register to access more free insights and analysis from Evaluate.
Register Now
|
|
|
|